Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Focus V (anlotinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Advenchen, Sino Biopharm

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

‹

›

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
EGFR negative	Non Small Cell Lung Cancer	EGFR negative	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2
EGFR negative	Non Small Cell Lung Cancer	EGFR negative	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria osimertinib + anlotinib Sensitive : C2	osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria osimertinib + anlotinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria osimertinib + anlotinib Sensitive : C2	osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria osimertinib + anlotinib Sensitive : C2